These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36788400)

  • 1. Next Generation Stem Cells and their Implications in Cancer Therapy.
    Sami A
    J Pak Med Assoc; 2023 Feb; 73(Suppl 1)(2):S98-S104. PubMed ID: 36788400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies.
    Sidhu I; Barwe SP; Pillai RK; Gopalakrishnapillai A
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
    Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
    Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling.
    Zhu D; Kong CSL; Gingold JA; Zhao R; Lee DF
    Adv Exp Med Biol; 2018; 1119():169-183. PubMed ID: 30069853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced pluripotent stem cells and hematological malignancies: A powerful tool for disease modeling and drug development.
    Donada A; Basso-Valentina F; Arkoun B; Monte-Mor B; Plo I; Raslova H
    Stem Cell Res; 2020 Dec; 49():102060. PubMed ID: 33142254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-Restricted Stem Cells as Starting Cell Source for Efficient Generation of Pluripotent Stem Cells: An Overview.
    Sundaravadivelu PK; Raina K; Thool M; Ray A; Joshi JM; Kaveeshwar V; Sudhagar S; Lenka N; Thummer RP
    Adv Exp Med Biol; 2022; 1376():151-180. PubMed ID: 34611861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced pluripotent stem cell (iPSCs) and their application in immunotherapy.
    Jiang Z; Han Y; Cao X
    Cell Mol Immunol; 2014 Jan; 11(1):17-24. PubMed ID: 24336163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Generation of Vascular Wall-Typical Mesenchymal Stem Cells (VW-MSC) from Murine Induced Pluripotent Stem Cells Through VW-MSC-Specific Gene Transfer.
    Steens J; Klump H; Klein D
    Methods Mol Biol; 2020; 2155():83-97. PubMed ID: 32474869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells.
    Li J; Song W; Pan G; Zhou J
    J Hematol Oncol; 2014 Jul; 7():50. PubMed ID: 25037625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced Pluripotency and Gene Editing in Fanconi Anemia.
    Navarro S; Giorgetti A; Raya A; Tolar J
    Curr Gene Ther; 2017; 16(5):321-328. PubMed ID: 28103772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation stem cells - ushering in a new era of cell-based therapies.
    Kimbrel EA; Lanza R
    Nat Rev Drug Discov; 2020 Jul; 19(7):463-479. PubMed ID: 32612263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer cells as a new source of induced pluripotent stem cells.
    Shamsian A; Sahebnasagh R; Norouzy A; Hussein SH; Ghahremani MH; Azizi Z
    Stem Cell Res Ther; 2022 Sep; 13(1):459. PubMed ID: 36064437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-Specific Integration of TRAIL in iPSC-Derived Mesenchymal Stem Cells for Targeted Cancer Therapy.
    Wang Z; Chen H; Wang P; Zhou M; Li G; Hu Z; Hu Q; Zhao J; Liu X; Wu L; Liang D
    Stem Cells Transl Med; 2022 Mar; 11(3):297-309. PubMed ID: 35267023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.
    Kaufman DS
    Blood; 2009 Oct; 114(17):3513-23. PubMed ID: 19652198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient generation of transgene- and feeder-free induced pluripotent stem cells from human dental mesenchymal stem cells and their chemically defined differentiation into cardiomyocytes.
    Tan X; Dai Q; Guo T; Xu J; Dai Q
    Biochem Biophys Res Commun; 2018 Jan; 495(4):2490-2497. PubMed ID: 29217199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of hematologic malignancies by iPS technology.
    Arai S; Miyauchi M; Kurokawa M
    Exp Hematol; 2015 Aug; 43(8):654-60. PubMed ID: 26135030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling blood diseases with human induced pluripotent stem cells.
    Georgomanoli M; Papapetrou EP
    Dis Model Mech; 2019 Jun; 12(6):. PubMed ID: 31171568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced Pluripotent Stem Cells as a Tool for Modeling Hematologic Disorders and as a Potential Source for Cell-Based Therapies.
    Pratumkaew P; Issaragrisil S; Luanpitpong S
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
    Zhu H; Kaufman DS
    Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation.
    Paes BCMF; Moço PD; Pereira CG; Porto GS; de Sousa Russo EM; Reis LCJ; Covas DT; Picanço-Castro V
    Cell Biol Toxicol; 2017 Jun; 33(3):233-250. PubMed ID: 28039590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.